SAB Biotherapeutics, Inc. (SABS) is a Healthcare stock trading at $3.77 (as of 2026-08-21), with a market capitalization of $288.27M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
SAB Biotherapeutics develops immunotherapies based on human antibodies, using its DiversitAb platform and transchromosomic bovine herds to produce fully human polyclonal antibodies targeted at diseases. How it makes money is not described in the provided facts.
The company’s profit model depends on its ability to turn the DiversitAb platform’s fully human antibody production into clinical progress for targeted diseases, ultimately leading to commercialization, since it is a clinical-stage biopharmaceutical company.
Business quality (Weak): Clinical-stage biotech with strong platform focus on fully human polyclonal antibodies, but the provided data shows no revenue and a very large operating loss, so near-term financial signals are weak and outcomes depend on ongoing clinical programs.
| Price | $3.77 |
| Market Cap | $288.27M |
| Price / Book | 1.27 |
| Price / Sales | 78.27 |
| FCF Yield | -5.3% |
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -106.0% |
| FCF Growth (YoY) | 32.0% |
| Altman Z-Score | 4.20 (safe) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | Vivo Capital, LLC ($43.74M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Samuel J. Reich |
| Employees | 63 |
| Country | US |
| IPO Date | 2021-02-09 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.